Read a new publication from Oncowitan: The review retraces the proteolytic origin of sTIM-3, the soluble form of the membrane immune checkpoint TIM-3 considered as a privileged target for the treatment of various cancers. This circulating protein is over expressed in a large diversity of human pathologies and can serve as a biomarker to follow disease evolution and response to treatment

Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseases, Biochemical Pharmacology (2023)

Read here

Categories: News-Publications